Evidence map›Paper›PMID 28702504›Full record

ReviewNPJ Parkinson's disease2017

Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects.

Peter Manza, Matthew Amandola, Vivekanand Tatineni, Chiang-Shan R Li, Hoi-Chung Leung

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ Parkinson's disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03665493 (Dopamine Effect on Inhibitory Control), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03665493 nacompletednot on this mapstarted 2020, after this paper: background citation

Dopamine Effect on Inhibitory Control

TypeinterventionalSponsorGiovanni MirabellaRan2020 to 2023Enrolled90ConditionsIdiopathic Parkinson's DiseaseArmsPD patients H&Y=1.5-2 Medications ON, PD patients H&Y=1.5-2 Medications OFF, Healthy age-matched controls, PD patients H&Y=3 Medications OFF, PD patients H&Y=3 Medications ON
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Observational
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Impulsivity traits and awareness of motor intention in Parkinson's disease: a proof-of-concept study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peter ManzaDepartment of Psychology, Stony Brook University, Stony Brook, NY 11790 USA.ORCID 0000-0002-0791-357X
Matthew AmandolaDepartment of Psychology, Stony Brook University, Stony Brook, NY 11790 USA.
Vivekanand TatineniDepartment of Psychology, Stony Brook University, Stony Brook, NY 11790 USA.
Chiang-Shan R LiDepartment of Psychiatry, Yale University, New Haven, CT 06519 USA.
Hoi-Chung LeungDepartment of Psychology, Stony Brook University, Stony Brook, NY 11790 USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease is a neurodegenerative disorder involving the basal ganglia that results in a host of motor and cognitive deficits. Dopamine-replacement therapy ameliorates some of the hallmark motor symptoms of Parkinson's disease, but whether these medications improve deficits in response inhibition, a critical executive function for behavioral control, has been questioned. Several studies of Parkinson's disease patients "on" and "off" (12-h withdrawal) dopaminergic medications suggested that dopamine-replacement therapy did not provide significant response inhibition benefits. However, these studies tended to include patients with moderate-to-advanced Parkinson's disease, when the efficacy of dopaminergic drugs is reduced compared to early-stage Parkinson's disease. In contrast, a few recent studies in early-stage Parkinson's disease report that dopaminergic drugs do improve response inhibition deficits. Based on these findings, we hypothesized that Parkinson's disease duration interacts with medication status to produce changes in cognitive function. To investigate this issue, we conducted a meta-analysis of studies comparing patients with Parkinson's disease and healthy controls on tests of response inhibition (50 comparisons from 42 studies). The findings supported the hypothesis; medication benefited response inhibition in patients with shorter disease duration, whereas "off" medication, moderate deficits were present that were relatively unaffected by disease duration. These findings support the role of dopamine in response inhibition and suggest the need to consider disease duration in research of the efficacy of dopamine-replacement therapy on cognitive function in Parkinson's disease.

Identifiers

PMID28702504
PMCPMC5501877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.